Literature DB >> 26649656

Reviving the promise of transcription factor Nrf2-based therapeutics for kidney diseases.

Sanjeev Noel1, Abdel R A Hamad2, Hamid Rabb1.   

Abstract

The transcription factor Nrf2 plays an important role in many kidney diseases from acute kidney injury to chronic kidney disease, and there have been preliminary Nrf2-based therapeutic trials in humans. Shelton et al. presents an integrated transcriptomic and proteomic analysis of mouse kidney to reveal Nrf2 targets with potentially important roles in kidney homeostasis and pathophysiology. These results can further our understanding of Nrf2-based mechanisms and help in the development of therapeutics for a wide range of kidney diseases.

Entities:  

Year:  2015        PMID： 26649656      PMCID： PMC5267352          DOI： 10.1038/ki.2015.328

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


  10 in total

1.  Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1.

Authors:  Qing Qing Wu; Yanxia Wang; Martin Senitko; Colin Meyer; W Christian Wigley; Deborah A Ferguson; Eric Grossman; Jianlin Chen; Xin J Zhou; John Hartono; Pamela Winterberg; Bo Chen; Anapam Agarwal; Christopher Y Lu
Journal:  Am J Physiol Renal Physiol       Date:  2011-02-02

2.  Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2.

Authors:  Lisa Kinch; Nick V Grishin; James Brugarolas
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

3.  T Lymphocyte-Specific Activation of Nrf2 Protects from AKI.

Authors:  Sanjeev Noel; Maria N Martina; Samatha Bandapalle; Lorraine C Racusen; Haranatha R Potteti; Abdel R A Hamad; Sekhar P Reddy; Hamid Rabb
Journal:  J Am Soc Nephrol       Date:  2015-08-20       Impact factor: 10.121

4.  Systemic inflammation and oxidative stress in hemodialysis patients are associated with down-regulation of Nrf2.

Authors:  Liliana M Pedruzzi; Ludmila F M F Cardozo; Julio B Daleprane; Milena B Stockler-Pinto; Elisa B Monteiro; Maurilo Leite; Nosratola D Vaziri; Denise Mafra
Journal:  J Nephrol       Date:  2015-01-14       Impact factor: 3.902

5.  Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemia-reperfusion injury.

Authors:  Martin O Leonard; Niamh E Kieran; Katherine Howell; Melissa J Burne; Raghu Varadarajan; Saravanakumar Dhakshinamoorthy; Alan G Porter; Cliona O'Farrelly; Hamid Rabb; Cormac T Taylor
Journal:  FASEB J       Date:  2006-12       Impact factor: 5.191

6.  Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.

Authors:  Melanie P Chin; Scott A Reisman; George L Bakris; Megan O'Grady; Peter G Linde; Peter A McCullough; David Packham; Nosratola D Vaziri; Keith W Ward; David G Warnock; Colin J Meyer
Journal:  Am J Nephrol       Date:  2014-06-03       Impact factor: 3.754

7.  Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

Authors:  Pablo E Pergola; Philip Raskin; Robert D Toto; Colin J Meyer; J Warren Huff; Eric B Grossman; Melissa Krauth; Stacey Ruiz; Paul Audhya; Heidi Christ-Schmidt; Janet Wittes; David G Warnock
Journal:  N Engl J Med       Date:  2011-06-24       Impact factor: 91.245

8.  Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice.

Authors:  Manchang Liu; Dmitry N Grigoryev; Michael T Crow; Mark Haas; Masayuki Yamamoto; Sekhar P Reddy; Hamid Rabb
Journal:  Kidney Int       Date:  2009-05-13       Impact factor: 10.612

9.  Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney.

Authors:  Luke M Shelton; Adam Lister; Joanne Walsh; Rosalind E Jenkins; Michael H L Wong; Cliff Rowe; Emanuele Ricci; Lorenzo Ressel; Yongxiang Fang; Philippe Demougin; Vanja Vukojevic; Paul M O'Neill; Christopher E Goldring; Neil R Kitteringham; B Kevin Park; Alex Odermatt; Ian M Copple
Journal:  Kidney Int       Date:  2015-09-30       Impact factor: 10.612

10.  The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia-reperfusion injury in mice.

Authors:  Manchang Liu; Narsa M Reddy; Elizabeth M Higbee; Haranatha R Potteti; Sanjeev Noel; Lorraine Racusen; Thomas W Kensler; Michael B Sporn; Sekhar P Reddy; Hamid Rabb
Journal:  Kidney Int       Date:  2013-10-02       Impact factor: 10.612
  10 in total
  10 in total

1.  Reduced Expression of Glutathione S-Transferase α 4 Promotes Vascular Neointimal Hyperplasia in CKD.

Authors:  Jinlong Luo; Guang Chen; Ming Liang; Aini Xie; Qingtian Li; Qunying Guo; Rajendra Sharma; Jizhong Cheng
Journal:  J Am Soc Nephrol       Date:  2017-11-10       Impact factor: 10.121

2.  KEAP1 Editing Using CRISPR/Cas9 for Therapeutic NRF2 Activation in Primary Human T Lymphocytes.

Authors:  Sanjeev Noel; Sul A Lee; Mohanraj Sadasivam; Abdel R A Hamad; Hamid Rabb
Journal:  J Immunol       Date:  2018-01-19       Impact factor: 5.422

Review 3.  Novel treatment strategies for chronic kidney disease: insights from the animal kingdom.

Authors:  Peter Stenvinkel; Johanna Painer; Makoto Kuro-O; Miguel Lanaspa; Walter Arnold; Thomas Ruf; Paul G Shiels; Richard J Johnson
Journal:  Nat Rev Nephrol       Date:  2018-01-15       Impact factor: 28.314

4.  Danshen modulates Nrf2-mediated signaling pathway in cisplatin-induced renal injury.

Authors:  Si-Si Cao; Miao Yan; Zhen-Yan Hou; Ying Chen; Yun-Sheng Jiang; Xin-Rong Fan; Ping-Fei Fang; Bi-Kui Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-10-20

5.  Downregulation of Glutathione Biosynthesis Contributes to Oxidative Stress and Liver Dysfunction in Acute Kidney Injury.

Authors:  Yue Shang; Yaw L Siow; Cara K Isaak; Karmin O
Journal:  Oxid Med Cell Longev       Date:  2016-10-30       Impact factor: 6.543

6.  Expression of the NRF2 Target Gene NQO1 Is Enhanced in Mononuclear Cells in Human Chronic Kidney Disease.

Authors:  Jianlin Shen; Marianne Rasmussen; Qi-Rong Dong; Martin Tepel; Alexandra Scholze
Journal:  Oxid Med Cell Longev       Date:  2017-07-13       Impact factor: 6.543

7.  Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.

Authors:  Federico Pio Fabrizio; Manuela Costantini; Massimiliano Copetti; Annamaria la Torre; Angelo Sparaneo; Andrea Fontana; Luana Poeta; Michele Gallucci; Steno Sentinelli; Paolo Graziano; Paola Parente; Vincenzo Pompeo; Laura De Salvo; Giuseppe Simone; Rocco Papalia; Francesco Picardo; Teresa Balsamo; Gerardo Paolo Flammia; Domenico Trombetta; Angela Pantalone; Klaas Kok; Ferronika Paranita; Lucia Anna Muscarella; Vito Michele Fazio
Journal:  Oncotarget       Date:  2017-02-14

8.  Association between Nrf2 and CDKN2A expression in patients with end-stage renal disease: a pilot study.

Authors:  Keiichi Sumida; Zhongji Han; Ankur A Dashputre; Praveen K Potukuchi; Csaba P Kovesdy
Journal:  Aging (Albany NY)       Date:  2020-07-13       Impact factor: 5.682

9.  Action of trichostatin A on Alzheimer's disease-like pathological changes in SH-SY5Y neuroblastoma cells.

Authors:  Li-Hua Li; Wen-Na Peng; Yu Deng; Jing-Jing Li; Xiang-Rong Tian
Journal:  Neural Regen Res       Date:  2020-02       Impact factor: 5.135

10.  Hypoxia-mediated regulation of mitochondrial transcription factors in renal epithelial cells: implications for hypertensive renal physiology.

Authors:  Bhargavi Natarajan; Vikas Arige; Abrar A Khan; S Santosh Reddy; Manoj K Barthwal; Nitish R Mahapatra
Journal:  Hypertens Res       Date:  2020-09-11       Impact factor: 3.872
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.